The number of activation symptoms a patient experienced (insomnia, irritability, hyperactivity, and impulsivity) was related to the CYP2C19 metabolizer status, with slower metabolizers experiencing more activation symptoms than faster metabolizers (p = 0.019, Figure 3B). The gene discussed is CYP2C19; the disease is insomnia measurement.